Literature DB >> 24935788

Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation.

Simone Brogi1, Stefania Butini, Samuele Maramai, Raffaella Colombo, Laura Verga, Cristina Lanni, Ersilia De Lorenzi, Stefania Lamponi, Marco Andreassi, Manuela Bartolini, Vincenza Andrisano, Ettore Novellino, Giuseppe Campiani, Margherita Brindisi, Sandra Gemma.   

Abstract

AIMS: We recently described multifunctional tools (2a-c) as potent inhibitors of human Cholinesterases (ChEs) also able to modulate events correlated with Aβ aggregation. We herein propose a thorough biological and computational analysis aiming at understanding their mechanism of action at the molecular level.
METHODS: We determined the inhibitory potency of 2a-c on Aβ1-42 self-aggregation, the interference of 2a with the toxic Aβ oligomeric species and with the postaggregation states by capillary electrophoresis analysis and transmission electron microscopy. The modulation of Aβ toxicity was assessed for 2a and 2b on human neuroblastoma cells. The key interactions of 2a with Aβ and with the Aβ-preformed fibrils were computationally analyzed. 2a-c toxicity profile was also assessed (human hepatocytes and mouse fibroblasts).
RESULTS: Our prototypical pluripotent analogue 2a interferes with Aβ oligomerization process thus reducing Aβ oligomers-mediated toxicity in human neuroblastoma cells. 2a also disrupts preformed fibrils. Computational studies highlighted the bases governing the diversified activities of 2a.
CONCLUSION: Converging analytical, biological, and in silico data explained the mechanism of action of 2a on Aβ1-42 oligomers formation and against Aβ-preformed fibrils. This evidence, combined with toxicity data, will orient the future design of safer analogues.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Alzheimer's disease; Amyloid beta oligomers; Amyloid beta peptides; Cholinesterase inhibitors; Molecular dynamics; Multifunctional ligands

Mesh:

Substances:

Year:  2014        PMID: 24935788      PMCID: PMC6493034          DOI: 10.1111/cns.12290

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  7 in total

1.  5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor.

Authors:  Li Wang; Ignacio Moraleda; Isabel Iriepa; Alejandro Romero; Francisco López-Muñoz; Mourad Chioua; Tsutomu Inokuchi; Manuela Bartolini; José Marco-Contelles
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

2.  Modulation of Amyloid β-Induced Microglia Activation and Neuronal Cell Death by Curcumin and Analogues.

Authors:  Ersilia De Lorenzi; Davide Franceschini; Cecilia Contardi; Rita Maria Concetta Di Martino; Francesca Seghetti; Massimo Serra; Federica Bisceglia; Andrea Pagetta; Morena Zusso; Federica Belluti
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

3.  Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment.

Authors:  Siqiang Lai; Min Zhang; Dongsheng Xu; Yiying Zhang; Lisha Qiu; Changhai Tian; Jialin Charlie Zheng
Journal:  Transl Neurodegener       Date:  2015-04-18       Impact factor: 8.014

4.  Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking.

Authors:  Margherita Brindisi; Simone Brogi; Nicola Relitti; Alessandra Vallone; Stefania Butini; Sandra Gemma; Ettore Novellino; Gianni Colotti; Gabriella Angiulli; Francesco Di Chiaro; Annarita Fiorillo; Andrea Ilari; Giuseppe Campiani
Journal:  Sci Rep       Date:  2015-05-07       Impact factor: 4.379

5.  Evidence that the Human Innate Immune Peptide LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly.

Authors:  Ersilia De Lorenzi; Marcella Chiari; Raffaella Colombo; Marina Cretich; Laura Sola; Renzo Vanna; Paola Gagni; Federica Bisceglia; Carlo Morasso; Jennifer S Lin; Moonhee Lee; Patrick L McGeer; Annelise E Barron
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Computational Approaches for Drug Discovery.

Authors:  Simone Brogi
Journal:  Molecules       Date:  2019-08-22       Impact factor: 4.411

Review 7.  Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations.

Authors:  Samuele Maramai; Mohamed Benchekroun; Moustafa T Gabr; Samir Yahiaoui
Journal:  Biomed Res Int       Date:  2020-06-30       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.